This immunotherapy is based on the discovery by the founding team members of the tumor antigen PPCT (Preprocalcitonin), a precursor of the hormone calcitonin (CT).
They demonstrated that PPCT, which is expressed or over-expressed in several human lung tumor types, is capable of inducing a specific immune response in many lung cancer patients and constitutes a promising candidate for an antitumor immunotherapy approach.
The ultimate goal is to develop a personalized vaccine composed not only of PPCT antigen, but also of peptides from mutated antigens identified in the tumor of each patient which will be the heart of the ElyssaTech® platform.
This technology differs from all other competing immunotherapy approaches as its mode of action will allow destruction of immune escape of tumors and its use in multi-resistant patients.
ElyssaMed® will develop the first therapeutic treatment for clinical use in non-small-cell lung cancer. This product once administered to lung cancer patients, will amplify their specific immune responses against cancer cells expressing the antigen PPCT and lead to their destruction.
The company plans to apply its first candidate drug to other cancers that express or over express PPCT, such as:
ElyssaMed stems from a discovery made at the Gustave Roussy Institute during the study of the remission of a cancer patient who had refused all forms of medical treatment.
Studying the immunological characteristics of this patient's tumor remission, Dr. Fathia Mami-Chouaib's INSERM U1186 "integrative tumor immunology and genetics oncology " was able to understand and mimic the underlying mechanism of tumor rejection.
This led to the development of ElyssaTech®: a revolutionary new approach to fight cancer.
Gustave Roussy is a pioneer in the demonstration of the center immunotheray's effectiveness in Europe, click on the logo to get more informations
A scientific advisory committee has been established to assist the company to define its scientific strategy for the successful development of these pharmaceuticals. It is chaired by Dr. Fathia MAMI-CHOUAIB and comprises:
ElyssaMed® develops multiple drug candidates targeting cancer based on a novel technological platform; its lead product EM-03 is developed to treat non-small cell lung cancer.
For decades, lung cancer has been the leading cause of cancer death in the world. Despite the possibilities of surgery and chemo- or radio-therapy treatments, only 15% of patients are still alive two years after diagnosis. Therefore lung cancer represents both a medical challenge and a socio-economic problem at the forefront of public health in Europe and the United States. ElyssaMed® will primarily target the cancer drug market. This market reached 60 billion Euro in 2012, including 6 billion in France. Its growth, estimated at 10.8% per year, is twice as fast as that of the entire pharmaceutical market.
The first cancer that will be targeted by the ElyssaMed® technology is the non-small cell lung cancer which account for 80% of lung cancers. However, the team's research studies have shown that other cancers could be targeted by the vaccine including medullary thyroid cancers (MTC), neuroendocrine tumors (NET) and small cell lung cancers (SCLC) as well as all tumors that express PPCT.
The latter pathologies include those that are classified as rare (orphan) diseases for which a facilitated and accelerated development of new treatments is permitted.
To receive our newsletter please register on our database by sending your name, email address